CBST looks pretty much out after the TSRX acquisition.
There are only five (5) BP's left with active antibacterial discovery programs according to
an article printed in the journal "Clinical Infectious Diseases" in January, 2009. They are:
GlaxoSmithKline; Novartis; AstraZeneca; Merck and Pfizer;
So there's our list gang... One of them will take us out; Another will take out CEMP;
Another TTPH ; IMHO... I own all three and owned TSRX too...GLTALs!
All I know is that we are a 340 million dollar market cap company right now. Trius I believe was taken out at a market value of around 800 million. Even if our ultimate value is less than that...say 500-600 million, we still have 50% upside from here. I'm thinking frankly $19 on the low end.